Abstract #2444

Multiparameter MRI Response Assessment in a Phase I Trial of Hypofractionated Stereotactic Irradiation with Pembrolizumab and Bevacizumab in Patients with Recurrent High Grade Gliomas

Olya Stringfield¹, John Arrington², Solmaz Sahebjam³, and Natarajan Raghunand¹

¹Cancer Imaging & Metabolism, Moffitt Cancer Center, Tampa, FL, United States, ²Radiology, Moffitt Cancer Center, Tampa, FL, United States, ³Neuro-Oncology, Moffitt Cancer Center, Tampa, FL, United States

In this ongoing phase 1 study, we are investigating combined pembrolizumab and bevacizumab therapy with hypofractionated radiotherapy in recurrent glioma. The objective of this work is to develop a non-invasive response assessment measure using multiparameter MRI (mpMRI) scans acquired as part of clinical care which may precede volumetric changes in response to therapy.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.